$INBX News

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT

HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences: The Whole Story Rides On INBRX-106

Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027

Inhibrx Reports First Quarter 2026 Financial Results

Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study

Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate

Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors?

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx Reports Interim Phase 2 Data For INBRX-106 in First-Line HNSCC

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

Inhibrx Biosciences To Present Interim Phase 2 HexAgon Study Results For INBRX-106 Plus Keytruda In Head And Neck Cancer On May 11, 2026 Webcast

Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory Momentum

Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans